Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
{
"resourceType" : "Group",
"id" : "179619",
"meta" : {
"versionId" : "4",
"lastUpdated" : "2023-12-06T00:11:33.141Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: Group</b><a name=\"179619\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Group "179619" Version "4" Updated "2023-12-06 00:11:33+0000" </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-systematic-review-eligibility-criteria.html\">SystematicReviewEligibilityCriteria</a></p></div><p><b>Artifact related artifact</b>: </p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>Artifact Title</b>: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</p><p><b>Artifact URL</b>: <a href=\"https://fevir.net/resources/Group/179619\">https://fevir.net/resources/Group/179619</a></p><p><b>Artifact Publisher</b>: Computable Publishing LLC</p><p><b>Artifact Copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>Artifact use context</b>: <span title=\"{https://fevir.net/resources/CodeSystem/179423 evidence-communication}\">Evidence Communication</span>: <span title=\"Codes: {https://fevir.net/resources/CodeSystem/179423 SystematicReviewEligibilityCriteria}\">SystematicReviewEligibilityCriteria</span></p><p><b>Artifact Contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>CombinationMethod</b>: all-of</p><blockquote><p><b>modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]</b></p></blockquote><p><b>identifier</b>: FEvIR Object Identifier:\u00a0179619</p><p><b>type</b>: animal</p><p><b>membership</b>: definitional</p><p><b>name</b>: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer</p><p><b>description</b>: **Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged ≥18 years with cytological or histological diagnosis of mHNPC.</p><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: Randomized controlled clinical trials (RCTs)</p><p><b>code</b>: Study Design <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>value</b>: randomized assignment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"CodeSystem-181513.html\">Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide</a>#SEVCO:01003)</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: parallel design</p><p><b>code</b>: Study Design <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>value</b>: Parallel cohort design <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"CodeSystem-181513.html\">Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide</a>#SEVCO:01011)</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: compared the association of ADT and chemotherapy (docetaxel), versus ADT alone</p><p><b>code</b>: Comparison <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>value</b>: <span>: GroupAssignment: ADT plus docetaxel vs. ADT alone</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: Types of participants.\nPatients aged ≥18 years</p><p><b>CharacteristicMethod</b>: applied to participants in the studies <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>code</b>: Age <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#397669002)</span></p><p><b>value</b>: >=18 years<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM code a = 'a')</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: Types of participants.\nPatients with cytological or histological diagnosis of mHNPC.</p><p><b>CharacteristicMethod</b>: applied to participants in the studies <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>CharacteristicMethod</b>: cytological or histological diagnosis <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>code</b>: Disease (disorder) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#64572001)</span></p><p><b>value</b>: metastatic hormone-naive prostate cancer <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>exclude</b>: false</p></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
"valueRelatedArtifact" : {
"type" : "cite-as",
"citation" : "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-04. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619."
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"name" : "Brian S. Alper"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-title",
"valueString" : "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-url",
"valueUri" : "https://fevir.net/resources/Group/179619"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-publisher",
"valueString" : "Computable Publishing LLC"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-copyright",
"valueMarkdown" : "https://creativecommons.org/licenses/by-nc-sa/4.0/"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-useContext",
"valueUsageContext" : {
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "SystematicReviewEligibilityCriteria",
"display" : "SystematicReviewEligibilityCriteria"
}
]
}
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-contact",
"valueContactDetail" : {
"telecom" : [
{
"system" : "email",
"value" : "support@computablepublishing.com"
}
]
}
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method",
"valueCode" : "all-of"
}
],
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-status",
"valueCode" : "active"
}
],
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "179619",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"type" : "animal",
"membership" : "definitional",
"name" : "SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer",
"description" : "**Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged ≥18 years with cytological or histological diagnosis of mHNPC.",
"characteristic" : [
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "Randomized controlled clinical trials (RCTs)"
}
],
"code" : {
"text" : "Study Design"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/181513",
"code" : "SEVCO:01003",
"display" : "randomized assignment"
}
]
},
"exclude" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "parallel design"
}
],
"code" : {
"text" : "Study Design"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/181513",
"code" : "SEVCO:01011",
"display" : "Parallel cohort design"
}
]
},
"exclude" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "compared the association of ADT and chemotherapy (docetaxel), versus ADT alone"
}
],
"code" : {
"text" : "Comparison"
},
"valueReference" : {
"type" : "EvidenceVariable",
"display" : "GroupAssignment: ADT plus docetaxel vs. ADT alone"
},
"exclude" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "Types of participants.\nPatients aged ≥18 years"
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method",
"valueCodeableConcept" : {
"text" : "applied to participants in the studies"
}
}
],
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "397669002",
"display" : "Age"
}
]
},
"valueQuantity" : {
"value" : 18,
"comparator" : ">=",
"unit" : "years",
"system" : "http://unitsofmeasure.org",
"code" : "a"
},
"exclude" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "Types of participants.\nPatients with cytological or histological diagnosis of mHNPC."
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method",
"valueCodeableConcept" : {
"text" : "applied to participants in the studies"
}
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method",
"valueCodeableConcept" : {
"text" : "cytological or histological diagnosis"
}
}
],
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "64572001",
"display" : "Disease (disorder)"
}
]
},
"valueCodeableConcept" : {
"text" : "metastatic hormone-naive prostate cancer"
},
"exclude" : false
}
]
}
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2023-12-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change